STOCK TITAN
  1. Home
  2. Sec-filings
  3. ONCY
  4. [8-K] ONCOLYTICS BIOTECH INC Reports Material Event

New pelareorep patent extends Oncolytics Biotech (Nasdaq: ONCY) IP to 2044

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Oncolytics Biotech Inc. filed an 8-K to share that the U.S. Patent and Trademark Office has issued a new patent covering key aspects of its proprietary manufacturing process for pelareorep. This patent is expected to protect commercial-scale production of the investigational immunotherapy into 2044 and strengthens the company’s intellectual property portfolio.

The company also highlighted a previously filed method-of-use patent application for pelareorep as an immunotherapy that, if granted, is expected to provide protection into 2046, and it plans additional patent filings in 2026. Pelareorep has shown encouraging results in multiple pancreatic, metastatic breast, anal, and colorectal cancer studies and has received Fast Track designation from the FDA for colorectal and pancreatic cancer.

Positive

  • None.

Negative

  • None.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Manufacturing patent protection horizon 2044 Expected protection period for new pelareorep manufacturing patent
Potential method-of-use patent horizon 2046 If the pending pelareorep method-of-use patent application is granted
Announcement date June 16, 2026 Date Oncolytics announced the new pelareorep patent
Fast Track indications Colorectal and pancreatic cancer FDA Fast Track designation for pelareorep in metastatic gastrointestinal cancers
intellectual property portfolio financial
"announcing a new patent related to the manufacturing of pelareorep and additional updates related to pelareorep's intellectual property portfolio"
A collection of a company’s legally recognized creations and rights—such as patents, trademarks, copyrights, trade secrets and licensing agreements—that together protect its products, brands and technologies. Think of it as the company’s toolbox or recipe box: some items keep competitors out, some can be rented or sold, and some enable unique products. For investors, the breadth and strength of this portfolio affect future revenue potential, competitive position and legal risk, so it influences valuation and investment decisions.
method-of-use patent application regulatory
"a previously filed method-of-use patent application directed at pelareorep’s use as an immunotherapy remains under review"
Fast Track designation regulatory
"pelareorep has received Fast Track designation from the FDA for colorectal and pancreatic cancer"
A "fast track designation" is a process that speeds up the review and approval of a product or project, allowing it to reach the market or be completed more quickly than usual. For investors, it can signal that a product may become available sooner, potentially leading to earlier revenue or benefits, and indicating a priority status that might influence company performance and market opportunities.
tertiary lymphoid structures technical
"including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures"
Clusters of immune cells that form in non-lymph node tissues, acting like pop-up immune hubs where white blood cells gather, communicate and organize a local defense. They matter to investors because their presence or absence can change how a disease progresses and how well immunotherapies work, so they can serve as biomarkers or influence the commercial prospects and regulatory outlook of drugs and diagnostics.
tumor-infiltrating lymphocytes technical
"resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes"
Tumor-infiltrating lymphocytes are immune cells that have moved from the blood into a tumor and are actively interacting with cancer cells. For investors, they matter because their presence and activity can signal how well a patient’s immune system — or an immune-based drug — is likely to fight the tumor, and they are also the basis for a personalized cell therapy approach where these cells are grown and returned to the patient, affecting clinical trial outcomes and commercial potential.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
FALSE0001129928A000011299282026-01-082026-01-08

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________
FORM 8-K
___________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 16, 2026
___________________________________
Oncolytics Biotech Inc.
(Exact name of registrant as specified in its charter)
___________________________________

Nevada
(State or other jurisdiction of
incorporation)
001-38512
(Commission File Number)
98-0541667
(IRS Employer Identification No.)
4350 Executive Drive, Suite 325
San Diego, CA 92121
92121
(Address of principal executive offices)
(Zip Code)
(403) 670-7377
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
___________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common stock, par value $0.001 per share
ONCY
The Nasdaq Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Exchange Act (§240.12b-2 of this chapter).
Emerging growth company    ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 8.01. Other Events.
On June 16, 2026, Oncolytics Biotech Inc. (the “Company”) issued a press release announcing a new patent related to the manufacturing of pelareorep and additional updates related to pelareorep's intellectual property portfolio. The information set forth in this Item 8.01 and in Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.

Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.

Exhibit No.
Description
99.1
Press Release issued by Oncolytics Biotech Inc., dated as of June 16, 2026.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).







SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 16, 2026
ONCOLYTICS BIOTECH INC.
By:
/s/ Kirk Look
Name:
Kirk Look
Title:
Chief Financial Officer





Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044

Intellectual property update confirms pelareorep’s unique manufacturing process and scalability

Previously filed method-of-use patent application expected to provide protection into 2046

Additional patent filings planned in 2026 to further expand the pelareorep intellectual property estate

SAN DIEGO, CA, June 16, 2026 – Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes, today announced that the United States Patent and Trademark Office (“USPTO”) has issued a new patent broadly protecting the Company's proprietary manufacturing process for pelareorep.

The newly issued patent covers key aspects of the methods used to manufacture pelareorep and is expected to provide intellectual property protection into 2044. The patent is designed to protect the Company’s ability to consistently produce pelareorep at commercial scale and represents a significant addition to Oncolytics’ growing intellectual property portfolio.

The Company also announced that a previously filed method-of-use patent application directed at pelareorep’s use as an immunotherapy remains under review and, if issued, is expected to provide protection into the year 2046. In addition, Oncolytics plans to file further patent applications this year that are designed to expand and strengthen the pelareorep intellectual property estate across additional therapeutic applications, treatment settings, and combination approaches.

“Building a strong intellectual property estate around pelareorep is an important part of our strategy as we advance the program toward potential registration and commercialization,” said Jared Kelly, Chief Executive Officer of Oncolytics. “This newly issued patent strengthens our protection around the manufacturing of pelareorep and supports our ability to produce the product at commercial scale. Combined with our previously filed method-of-use patent application and additional planned filings, we continue to build a durable patent portfolio designed to support the long-term value of pelareorep. Checking this box represents another important milestone as we execute on our strategy and move pelareorep into its next phase of development.”

The Company’s intellectual property strategy is focused on protecting pelareorep through a combination of manufacturing, method-of-use, formulation, and combination therapy patents designed to support the continued development and commercialization of pelareorep across multiple oncology indications.

About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It is designed to induce anti-cancer immune responses by converting immunologically “cold” tumors to “hot” through the activation of innate and adaptive immune responses.



The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic gastrointestinal cancers, where pelareorep has received Fast Track designation from the FDA for colorectal and pancreatic cancer. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: www.oncolyticsbiotech.com or follow the Company on LinkedIn and on X @oncolytics.

Forward-looking statements
This press release contains forward-looking statements, within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as “forward-looking statements”). Forward-looking statements contained in this press release include statements regarding beliefs as to the potential, registration, mechanism of action and benefits of pelareorep as a cancer therapeutic; the Company’s goals, strategies, and objectives; expectations around the design, milestones, anticipated timelines and expected outcomes for current and future studies, its belief in the clinical promise of pelareorep in anal, colorectal, pancreatic and other gastrointestinal cancers; the Company’s goals and expectations for its potential registrational development path for pelareorep in multiple gastrointestinal cancers; and plans for future disclosure of clinical trial results. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those anticipated. These risks include, but are not limited to, regulatory outcomes, trial execution, financial resources, access to capital markets, and market dynamics. Please refer to Oncolytics’ public filings with securities regulators in the United States and Canada for more information. The Company assumes no obligation to update forward-looking statements, except as required by law.


Company Contact
Jon Patton
Director of IR & Communication
jpatton@oncolytics.com


Source: View Original Filing on SEC EDGAR

FAQ

What did Oncolytics Biotech (ONCY) announce in its latest 8-K filing?

Oncolytics Biotech announced a new U.S. patent covering key aspects of its proprietary pelareorep manufacturing process, expected to protect commercial-scale production into 2044, along with updates on additional current and planned patent filings for pelareorep.

How long does the new pelareorep manufacturing patent protect Oncolytics Biotech (ONCY)?

The newly issued U.S. patent for pelareorep’s proprietary manufacturing process is expected to provide intellectual property protection into 2044. It is designed to safeguard consistent, commercial-scale production and forms a significant part of Oncolytics Biotech’s growing pelareorep-focused intellectual property portfolio.

What is the status of Oncolytics Biotech’s pelareorep method-of-use patent application?

A previously filed method-of-use patent application for pelareorep as an immunotherapy remains under review. If granted, it is expected to provide intellectual property protection into 2046, complementing the new manufacturing patent and planned additional filings in 2026.

In which cancer indications has pelareorep shown encouraging results for Oncolytics Biotech (ONCY)?

Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. These data support its continued development as an intravenously delivered immunotherapeutic agent.

Does pelareorep have any FDA Fast Track designations for Oncolytics Biotech (ONCY)?

Pelareorep has received Fast Track designation from the U.S. Food and Drug Administration for colorectal and pancreatic cancer. This designation supports its clinical development in metastatic gastrointestinal cancers, where Oncolytics is advancing pelareorep with chemotherapy and checkpoint inhibitor combinations.

How does Oncolytics Biotech plan to expand pelareorep’s intellectual property estate?

Oncolytics Biotech plans additional pelareorep patent applications in 2026 focused on manufacturing, method-of-use, formulation, and combination therapies. These filings are designed to broaden protection across therapeutic applications, treatment settings, and combination approaches, supporting long-term development and potential commercialization.

Filing Exhibits & Attachments

4 documents

Press Releases

Other Documents